The CXCR3(+)CD56Bright Phenotype Characterizes a Distinct NK Cell Subset with Anti-Fibrotic Potential That Shows Dys-Regulated Activity in Hepatitis C
暂无分享,去创建一个
J. Nattermann | H. Nischalke | T. Sauerbruch | U. Spengler | B. Krämer | C. Körner | A. Glässner | P. Kokordelis | B. Sibbing | Marianne Eisenhardt
[1] David L. Thomas,et al. CXCL9 and CXCL10 chemokines as predictors of liver fibrosis in a cohort of primarily African-American injection drug users with chronic hepatitis C. , 2011, The Journal of infectious diseases.
[2] F. Tacke,et al. Serum chemokine receptor CXCR3 ligands are associated with progression, organ dysfunction and complications of chronic liver diseases , 2011, Liver international : official journal of the International Association for the Study of the Liver.
[3] W. Jeong,et al. Suppression of innate immunity (natural killer cell/interferon‐γ) in the advanced stages of liver fibrosis in mice , 2011, Hepatology.
[4] A. Casrouge,et al. Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV. , 2011, The Journal of clinical investigation.
[5] Céline Hernandez,et al. Hepatitis C Virus (HCV) Evades NKG2D-Dependent NK Cell Responses through NS5A-Mediated Imbalance of Inflammatory Cytokines , 2010, PLoS pathogens.
[6] S. Friedman,et al. Amelioration of hepatic fibrosis by NK cell activation , 2010, Gut.
[7] Marianthi Markatou,et al. Peripheral CXCR3-associated chemokines as biomarkers of fibrosis in chronic hepatitis C virus infection. , 2009, The Journal of infectious diseases.
[8] G. Michelone,et al. Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. , 2009, Gastroenterology.
[9] C. Tinelli,et al. Prospective study of natural killer cell phenotype in recurrent hepatitis C virus infection following liver transplantation. , 2009, Journal of hepatology.
[10] L. Chiriboga,et al. Intrahepatic levels of CXCR3‐associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C , 2008, Hepatology.
[11] W. Jeong,et al. Innate immunity and alcoholic liver fibrosis , 2008, Journal of gastroenterology and hepatology.
[12] W. Jeong,et al. Abrogation of the antifibrotic effects of natural killer cells/interferon-gamma contributes to alcohol acceleration of liver fibrosis. , 2008, Gastroenterology.
[13] W. Jeong,et al. Activation of natural killer cells inhibits liver fibrosis: a novel strategy to treat liver fibrosis , 2007, Expert review of gastroenterology & hepatology.
[14] W. Jeong,et al. Retinoic acid signaling sensitizes hepatic stellate cells to NK cell killing via upregulation of NK cell activating ligand RAE1. , 2007, American journal of physiology. Gastrointestinal and liver physiology.
[15] A. Neumann,et al. IP‐10 predicts viral response and therapeutic outcome in difficult‐to‐treat patients with HCV genotype 1 infection , 2006, Hepatology.
[16] W. Jeong,et al. STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicity , 2006, Hepatology.
[17] A. Neumann,et al. Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. , 2006, The Journal of infectious diseases.
[18] S. Friedman,et al. Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC. , 2006, Journal of Hepatology.
[20] A. E. Yeo,et al. Decreased NK cell frequency in chronic hepatitis C does not affect ex vivo cytolytic killing , 2006, Hepatology.
[21] R. Sun,et al. Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. , 2006, Gastroenterology.
[22] M. Diago,et al. Association of pretreatment serum interferon γ inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C , 2005, Gut.
[23] Andrew H Talal,et al. Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. , 2005, Blood.
[24] S. McColl,et al. Expression of the CXCR3 ligand I‐TAC by hepatocytes in chronic hepatitis C and its correlation with hepatic inflammation , 2004, Hepatology.
[25] Rakesh K. Kumar,et al. Expression of the chemokine IP‐10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation , 2003, Journal of leukocyte biology.
[26] D. Doherty,et al. Resident human hepatic lymphocytes are phenotypically different from circulating lymphocytes. , 1998, Journal of hepatology.